Biologic Therapies for Giant Cell Arteritis

References

• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461. doi:10.1002/art.24459
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in north-western Spain: a 25-year epidemiologic study. Medicine. 2007;86:61–68. doi:10.1097/md.0b013e31803d1764
   PubMed Web of Science ®Google Scholar
• Prior JA, Ranjbar H, Belcher J, et al. Diagnostic delay for giant cell arteritis – a systematic review and meta-analysis. BMC Med. 2017;15:120. doi:10.1186/s12916-017-0871-z
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med. 2002;347:261–271. doi:10.1056/NEJMra011913
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015;17:6. doi:10.1007/s11926-014-0480-1
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Castañeda S, Llorca J. Giant cell arteritis: visual loss is our major concern. J Rheumatol. 2016;43:1458–1461. doi:10.3899/jrheum.160466
   PubMed Web of Science ®Google Scholar
• Low C, Conway R. Current advances in the treatment of giant cell arteritis: the role of biologics. Ther Adv Musculoskelet Dis. 2019. doi:10.1177/1759720X19827222
   Web of Science ®Google Scholar
• Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309–315. doi:10.3899/jrheum.140188
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532–3537. doi:10.1002/art.11480
   PubMed Web of Science ®Google Scholar
• García-Martínez A, Arguis P, Prieto-González S, et al. Prospective long-term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73:1826–1832. doi:10.1136/annrheumdis-2013-203322
   PubMed Web of Science ®Google Scholar
• Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3522–3531. doi:10.1002/art.11353
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from north-western Spain. Medicine. 2011;90:186–193. doi:10.1097/MD.0b013e31821c4fad
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant cell arteritis. N Engl J Med. 2017;377:317–328. doi:10.1056/NEJMoa1613849
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11. doi:10.1002/art.37715
   PubMed Web of Science ®Google Scholar
• Weyand CM. Younge BR and Goronzy JJ. IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43–49. doi:10.1097/BOR.0b013e32833ee946
   PubMed Web of Science ®Google Scholar
• Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402(5):797–812. doi:10.1016/j.jmb.2010.07.046
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, Gallagher P, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578–1579.
   Google Scholar
• Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–57. doi:10.1056/NEJMcp1214825
   PubMed Web of Science ®Google Scholar
• Choy E. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2018;58(6):pp.953–962. doi:10.1093/rheumatology/key339
   Web of Science ®Google Scholar
• Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456–458. doi:10.1093/rheumatology/29.6.456
   PubMedGoogle Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology. 2004;43:294–301. doi:10.1093/rheumatology/keh058
   PubMed Web of Science ®Google Scholar
• Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–491. doi:10.7326/0003-4819-121-7-199410010-00003
   PubMed Web of Science ®Google Scholar
• Koster M, Warrington K. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatology. 2017;1:1. doi:10.1186/s41927-017-0004-5
   Google Scholar
• Boes CJ. Bayard Horton’s clinicopathological description of giant cell (temporal) arteritis. Cephalalgia. 2007;27:68–75. doi:10.1111/j.1468-2982.2007.01238.x
   Web of Science ®Google Scholar
• Shick RM, Baggenstoss AH, Fuller BF, et al. Effects of cortisone and ACTH on periarteritis nodosa and cranial arteritis. Proc Staff Meet Mayo Clin. 1950;25:492–494.
   Web of Science ®Google Scholar
• Maleszewski JJ, Younge BR, Fritzlen JT, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017;30:788–796. doi:10.1038/modpathol.2017.10
   PubMed Web of Science ®Google Scholar
• Scheurer RA, Harrison AR, Lee MS. Treatment of vision loss in giant cell arteritis. Curr Treat Options Neurol. 2012;14(1):84–92. doi:10.1007/s11940-011-0152-7
   Web of Science ®Google Scholar
• Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol. 2012;32(3):278–287. doi:10.1097/WNO.0b013e3182688218
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114. doi:10.7326/0003-4819-134-2-200101160-00010
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–1318. doi:10.1002/art.10262
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789–2797. doi:10.1002/art.22754
   PubMed Web of Science ®Google Scholar
• Mackie S, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology. 2020;59(3):e1–e23. doi:10.1093/rheumatology/kez672
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30. doi:10.1136/annrheumdis-2019-215672
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP. Hetland H and Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. doi:10.1155/2013/120638
   PubMed Web of Science ®Google Scholar
• Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66:906–909. doi:10.1111/j.1742-1241.2012.02981.x
   PubMed Web of Science ®Google Scholar
• Loock J, Henes J, Kotter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012;30:S70–S76.
   PubMed Web of Science ®Google Scholar
• De Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43:105–112.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology. 2012;51:1677–1686. doi:10.1093/rheumatology/kes127
   PubMed Web of Science ®Google Scholar
• Ly KH, Dalmay F, Gondran G, et al. Steroid sparing effect and toxicity of dapsone treatment in giant cell arteritis: a single-center, retrospective study of 70 patients. Medicine. 2016;95:e4974. doi:10.1097/MD.0000000000004974
   PubMed Web of Science ®Google Scholar
• Dospinescu P, Karabayas M, Kidder D, et al. Mycophenolate mofetil versus methotrexate in the management of large vessel giant cell arteritis. Ann Rheum Diseases. 2016;75:798. doi:10.1136/annrheumdis-2016-eular.4330
   Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Diseases. 1986;45:136–138. doi:10.1136/ard.45.2.136
   PubMed Web of Science ®Google Scholar
• Sailler L, Lapeyre-Mestre M, Geffray L, et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial. Arthritis Rheum. 2009;60:1972.
   Google Scholar
• Schaufelberger C. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol. 1998;37:464–465. doi:10.1093/rheumatology/37.4.464
   PubMedGoogle Scholar
• Schaufelberger C, Mollby H, Uddhammar A, et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35:327–329. doi:10.1080/03009740500474537
   PubMed Web of Science ®Google Scholar
• De Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105–112. doi:10.1016/j.semarthrit.2012.12.023
   PubMed Web of Science ®Google Scholar
• Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest. 1994;94:1134–1140. doi:10.1172/JCI117428
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow-up of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835–841. doi:10.1002/acr.20043
   PubMed Web of Science ®Google Scholar
• Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013;25:3–9. doi:10.1097/BOR.0b013e32835b133a
   PubMed Web of Science ®Google Scholar
• O’Neill L, McCormick J, Gao W, et al. Interleukin 6 does not upregulate pro inflammatory cytokine expression in an ex-vivo model of giant cell arteritis. Arthritis Rheumatol. 2014;66:S391.
   Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation. 2003;107:2428–2434. doi:10.1161/01.CIR.0000066907.83923.32
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921–1927. doi:10.1016/S0140-6736(16)00560-2
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T, Prieto-Peña D, Calderon-Goercke M, Blanco R, Castañeda S. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. Expert Rev Clin Immunol. 2018;14:593–605. doi:10.1080/1744666X.2018.1485491
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Dasgupta B, Luqmani R, et al. A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis. Rheumatology and Therapy. 2020;7(4):793–810. doi:10.1007/s40744-020-00227-2
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, McCarthy GM, et al. Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Ann Rheum Dis. 2018;77(12):1815–1824. doi:10.1136/annrheumdis-2018-213488
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578–1579. doi:10.1136/annrheumdis-2016-209351
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, Gallagher P, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48(3):523–528. doi:10.1016/j.semarthrit.2018.04.004
   PubMed Web of Science ®Google Scholar
• Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the treatment of giant cell arteritis published online ahead of print, 2020 Apr 5. Arthritis Care Res. 2020. doi:10.1002/acr.24200
   Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–630. doi:10.7326/0003-4819-146-9-200705010-00004
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–2081. doi:10.1136/annrheumdis-2013-203586
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625–630. doi:10.1136/ard.2007.082115
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837–845. doi:10.1002/art.40044
   PubMed Web of Science ®Google Scholar
• Hartmann B, Liao J, Weisman MH, Warrington KJ, Goronzy JJ, Weyand CM The STAT1 signalling pathway in giant cell arteritis. Meeting: 2013 ACR/ARHP Annual Meeting; San Diego, California, USA; Abstract Number: 1691
   Google Scholar
• Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signalling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137:1934–1948. doi:10.1161/CIRCULATIONAHA.117.030423
   PubMed Web of Science ®Google Scholar
• Van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66:1927–1938. doi:10.1002/art.38625
   PubMed Web of Science ®Google Scholar
• Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum. 1989;32:884–893.
   PubMed Web of Science ®Google Scholar
• Alba MA, Prieto-Gonzalez S, Hernandez-Rodriguez J, Cid MC. B lymphocytes may play a significant role in large vessel vasculitis. Future Med. 2012;7:475–477.
   Google Scholar
• Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099–1100. doi:10.1136/ard.2005.036533
   PubMed Web of Science ®Google Scholar
• Mayrbaeurl B, Hinterreiter M, Burgstaller S, et al. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007;26(9):1597–1598. doi:10.1007/s10067-007-0684-0
   PubMed Web of Science ®Google Scholar
• Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81:76–78. doi:10.1016/j.jbspin.2013.06.004
   PubMed Web of Science ®Google Scholar
• Cid MC, Muralidharan S, Corbera-Bellalta M, et al. FRI0010 GM-CSFR pathway is implicated is implicated in pathogenic inflammatory mechanisms in giant cell arteritis. Ann Rheum Dis. 2020;79:576.
   Web of Science ®Google Scholar
• Burmester GR, McInnes IB, on behalf of the EARTH EXPLORER 1 study investigators, et al. A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 76;2017:1020–1030. doi:10.1136/annrheumdis-2016-210624
   PubMed Web of Science ®Google Scholar
• Cid M, Unizony S, Pupim L, et al. Mavrilimumab (anti GM-CSF receptor α monoclonal antibody) reduces time to flare and increases sustained remission in a phase 2 trial of patients with giant cell arteritis [abstract]. Arthritis Rheumatol. 2020;72(suppl 10).
   Google Scholar
• Rotar Ž, Tomšic M, Hocevar A. Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. Rheumatology. 2018;57:934–936. doi:10.1093/rheumatology/kex507
   PubMed Web of Science ®Google Scholar
• Sammut L, Litwic A, Smith R, et al. 002 Biopsy proven giant cell arteritis in a patient with psoriatic arthritis on TNF-alpha inhibitor treated with high dose prednisolone and a switch to secukinumab (anti IL-17). Rheumatology. 2018;57(suppl_3):key075.226. doi:10.1093/rheumatology/key075.226
   Google Scholar